According to scientists, drugs that are used for diabetes mellitus type two can lead to a reduced risk of developing Parkinson's disease.
Norwegian scientists found that in patients who used the drug Glutazone (GTZ), the risk of developing degenerative disease was a quarter lower, if we consider the percentage. GTZ, known in Russia as Thiazolidinedione, is used in the second type of diabetes. With it, you can increase the sensitivity of the body to insulin, which is responsible for regulating blood sugar levels.
In order to detect the connection between the use of GTZ and Parkinson's disease, the scientists performed an analysis of the patients to whom the drug was given for its intended purpose. The researchers also drew attention to how metformin, which is part of the drug prescribed for the second type of diabetes, affects the development of Parkinson's disease. For ten years from January 2005 to December 2014, researchers have identified more than 94.3 thousand people who use Metformin, and almost 8.4 thousand GTZ.
According to the results of scientific work, it was shown that patients who used the new drug had a lower tendency to develop Parkinson's disease by almost a third. Scientists do not have enough information to accurately explain the mechanism that underlies their findings, but they believe that GTZ leads to better mitochondrial work.
"Perhaps, GTZ preparations increase the synthesis of mitochondrial DNA and the total mass of the same name," the study authors say.
According to scientists, the study may become the basis of new strategic approaches in terms of the prevention and treatment of Parkinson's disease.
"The new information that we discovered makes the solution of issues related to Parkinson's disease closer," the author says.